Clinical Trial Update: Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial investigating antithymocyte globulin, clofarabine, and rituximab after unsuccessful stem cell transplant; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Antithymocyte Globulin (anti-thymocyte globulin)
• Clofarabine (clofarabine)
• Rituximab (rituximab)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-01-20